Clinical trial
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
NCT00224874 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00224874 |
|---|---|
| Title | Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) |
| Official title | Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302) |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Collaborators | National Cancer Institute (NCI) NIH Blood and Marrow Transplant Clinical Trials Network |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease, Immune System Disorders |
| Intervention type | Drug |
| Interventions | Etanercept, Mycophenolate Mofetil, Denileukin Diftitox, Pentostatin |
| Enrollment | 180 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jun 1, 2012 |
| First posted | Sep 23, 2005 |
| Last update posted | Nov 1, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: